BMC Cancer (May 2020)

Independence of HIF1a and androgen signaling pathways in prostate cancer

  • Maxine G. B. Tran,
  • Becky A. S. Bibby,
  • Lingjian Yang,
  • Franklin Lo,
  • Anne Y. Warren,
  • Deepa Shukla,
  • Michelle Osborne,
  • James Hadfield,
  • Thomas Carroll,
  • Rory Stark,
  • Helen Scott,
  • Antonio Ramos-Montoya,
  • Charlie Massie,
  • Patrick Maxwell,
  • Catharine M. L. West,
  • Ian G. Mills,
  • David E. Neal

DOI
https://doi.org/10.1186/s12885-020-06890-6
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background Therapeutic targeting of the androgen signaling pathway is a mainstay treatment for prostate cancer. Although initially effective, resistance to androgen targeted therapies develops followed by disease progression to castrate-resistant prostate cancer (CRPC). Hypoxia and HIF1a have been implicated in the development of resistance to androgen targeted therapies and progression to CRCP. The interplay between the androgen and hypoxia/HIF1a signaling axes was investigated. Methods In vitro stable expression of HIF1a was established in the LNCaP cell line by physiological induction or retroviral transduction. Tumor xenografts with stable expression of HIF1a were established in castrated and non-castrated mouse models. Gene expression analysis identified transcriptional changes in response to androgen treatment, hypoxia and HIF1a. The binding sites of the AR and HIF transcription factors were identified using ChIP-seq. Results Androgen and HIF1a signaling promoted proliferation in vitro and enhanced tumor growth in vivo. The stable expression of HIF1a in vivo restored tumor growth in the absence of endogenous androgens. Hypoxia reduced AR binding sites whereas HIF binding sites were increased with androgen treatment under hypoxia. Gene expression analysis identified seven genes that were upregulated both by AR and HIF1a, of which six were prognostic. Conclusions The oncogenic AR, hypoxia and HIF1a pathways support prostate cancer development through independent signaling pathways and transcriptomic profiles. AR and hypoxia/HIF1a signaling pathways independently promote prostate cancer progression and therapeutic targeting of both pathways simultaneously is warranted.

Keywords